Quick Takeaways
- GOLDMAN SACHS GROUP INC filed SCHEDULE 13G for TAYSHA GENE THERAPIES, INC. Common Stock, par value $0.00001 per share (TSHA).
- Disclosed ownership: 5.1%.
- Date of event: 26 Jun 2025.
GOLDMAN SACHS GROUP INC - 26 Jun 2025 SCHEDULE 13G Report for TAYSHA GENE THERAPIES, INC. Common Stock, par value $0.00001 per share (TSHA)
- Filing Manager
- GOLDMAN SACHS GROUP INC
- Reporting Manager
- THE GOLDMAN SACHS GROUP, INC.
- Symbol
- TSHA
- Shares outstanding
- 249,979,765 shares
- Disclosed Ownership
- 12,748,968 shares
- Ownership
- 5.1%
- Form type
- SCHEDULE 13G
- Filing time
- 03 Jul 2025, 12:23:57 UTC
- Date of event
- 26 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GOLDMAN SACHS GROUP INC disclosed 5.1% ownership in TAYSHA GENE THERAPIES, INC. Common Stock, par value $0.00001 per share (TSHA) on 26 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Jul 2025, 12:23.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| THE GOLDMAN SACHS GROUP, INC. | 5.1% | 12,748,968 | 0 | 12,748,918 | Name:Ameen Soetan | Attorney-in-fact | |
| GOLDMAN SACHS & CO. LLC | 5.1% | 12,748,968 | 0 | 12,748,918 | Name:Ameen Soetan | Attorney-in-fact |